Tenderwize
Retour à la recherche

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 132 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Mepolizumab, ATC R03DX09

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 28, 2027

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for the active substance Mepolizumab (ATC R03DX09).
  • Contracts are open to all interested pharmaceutical companies under uniform terms.
Afficher le résumé complet

Open House model for non-exclusive discount agreements on Mepolizumab (ATC R03DX09) offered by AOK Rheinland-Pfalz/Saarland. Any pharmaceutical company with authorized and marketable Mepolizumab products in Germany can join. Contracts run up to 24 months from May 1, 2025 to April 30, 2027, with rolling join dates. The procedure is not subject to EU procurement law despite using a standard notice form. No estimated value is provided.

Risques

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only authorized and marketable medicinal products in Germany may be supplied.
  • Proof of authorization and marketability required (Lauer-Taxe listing or AMIce database extract).

Certifications

  • For products not yet listed, additional documentation (e.g., approval certificate) must be provided.

Critères d'attribution

Lot 1

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

Non-exclusive discount agreement for Mepolizumab. Any pharmaceutical company meeting eligibility can sign up. Contracts valid until April 30, 2027. The AOK reserves the right to replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Date limite

Deadline Feb 28, 2027

Détails de la procédure

Date de publication
12 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
165250-2025

Documents (1)

Appels d'offres similaires